Frits Rosendaal
Frits Rosendaal
hoogleraar Klinische Epidemiologie, Leiden University Medical Center
Verified email at
Cited by
Cited by
Heart disease and stroke statistics—2017 update: a report from the American Heart Association
EJ Benjamin, MJ Blaha, SE Chiuve, M Cushman, SR Das, R Deo, ...
circulation 135 (10), e146-e603, 2017
Heart disease and stroke statistics 2005 update
American Heart Association
http://www. americanheart. org/statistics/, 2005
Mutation in blood coagulation factor V associated with resistance to activated protein C
RM Bertina, BPC Koeleman, T Koster, FR Rosendaal, RJ Dirven, ...
Nature 369 (6475), 64-67, 1994
A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
SR Poort, FR Rosendaal, PH Reitsma, RM Bertina
The Scylla and Charybdis of oral anticoagulant treatment
FR Rosendaal
New England Journal of Medicine 335 (8), 587-589, 1996
Malignancies, prothrombotic mutations, and the risk of venous thrombosis
JW Blom, CJM Doggen, S Osanto, FR Rosendaal
Jama 293 (6), 715-722, 2005
A method to determine the optimal intensity of oral anticoagulant therapy
FR Rosendaal, SC Cannegieter, FJM Van der Meer, E Briet
Thrombosis and haemostasis 69 (03), 236-239, 1993
Venous thrombosis: a multicausal disease
FR Rosendaal
The Lancet 353 (9159), 1167-1173, 1999
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease
H Schunkert, IR Knig, S Kathiresan, MP Reilly, TL Assimes, H Holm, ...
Nature genetics 43 (4), 333-338, 2011
Incidence and mortality of venous thrombosis: a population‐based study
IA Nss, SC Christiansen, P Romundstad, SC Cannegieter, ...
Journal of thrombosis and haemostasis 5 (4), 692-699, 2007
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
T Koster, JP Vandenbroucke, FR Rosendaal, H De Ronde, E Brit, ...
The Lancet 342 (8886-8887), 1503-1506, 1993
Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis
T Koster, JP Vandenbroucke, FR Rosendaal, E Brit, AD Blann
The Lancet 345 (8943), 152-155, 1995
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
JP Vandenbroucke, T Koster, FR Rosendaal, E Brit, PH Reitsma, ...
The Lancet 344 (8935), 1453-1457, 1994
Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
M Den Heijer, T Koster, HJ Blom, GMJ Bos, E Brit, PH Reitsma, ...
New England journal of medicine 334 (12), 759-762, 1996
High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)[see comments]
FR Rosendaal, T Koster, JP Vandenbroucke, PH Reitsma
The risk of myocardial infarction associated with antihypertensive drug therapies
BM Psaty, SR Heckbert, TD Koepsell, DS Siscovick, TE Raghunathan, ...
Jama 274 (8), 620-625, 1995
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study
KM Musallam, HM Tamim, T Richards, DR Spahn, FR Rosendaal, ...
The Lancet 378 (9800), 1396-1407, 2011
Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses.
SC Cannegieter, FR Rosendaal, E Briet
Circulation 89 (2), 635-641, 1994
Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials
Homocysteine Lowering Trialists' Collaboration
Bmj 316 (7135), 894-898, 1998
Optimal oral anticoagulant therapy in patients with mechanical heart valves
SC Cannegieter, FR Rosendaal, AR Wintzen, FJM Van der Meer, ...
New England Journal of Medicine 333 (1), 11-17, 1995
The system can't perform the operation now. Try again later.
Articles 1–20